2026 · 3rd Quarter (July 1 - Sep 30)

BIOMARIN PHARMACEUTICAL INC.

Filed by BIOMARIN PHARMACEUTICAL INC..

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2026
Income: Not reported
Expenses: $200,000.00
Registrant: BIOMARIN PHARMACEUTICAL INC.
Client: BIOMARIN PHARMACEUTICAL INC.
Filing UUID: e2f8c0b5-d05d-4125-8522-f6920b2dcae0
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

H.R.10571: SURGE TO SAVE NEWBORNS ACT; PROVISIONS RELATED TO NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING

Literal federal measure citations: H.R.10571

MMM · Medicare/Medicaid

GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT

TAR · Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING TARIFFS

MED · Medical/Disease Research/Clinical Labs

H.R.10359: PRIORITY FOR PEDIATRIC CURES ACT; PROVISIONS RELATED TO REMOVAL OF RARE PEDIATRIC PRIORITY REVIEW VOUCHERS SUNSET GENERAL DISCUSSIONS REGARDING CLINICAL TRIALS

Literal federal measure citations: H.R.10359

TAX · Taxation/Internal Revenue Code

H.R. 1414: CAMERON'S LAW; ALL PROVISIONS

Literal federal measure citations: H.R. 1414

CPT · Copyright/Patent/Trademark

DISCUSSIONS REGARDING INTELLECTUAL PROPERTY AND U.S. INTERNATIONAL TRADE COMMISSION EXCLUSION ORDER

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.